<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Inflam</journal-id><journal-id journal-id-type="iso-abbrev">Int J Inflam</journal-id><journal-id journal-id-type="publisher-id">IJI</journal-id><journal-title-group><journal-title>International Journal of Inflammation</journal-title></journal-title-group><issn pub-type="ppub">2090-8040</issn><issn pub-type="epub">2042-0099</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3356881</article-id><article-id pub-id-type="pmid">22645700</article-id><article-id pub-id-type="doi">10.1155/2012/712739</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kyhälä</surname><given-names>Lea</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mentula</surname><given-names>Panu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kylänpää</surname><given-names>Leena</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moilanen</surname><given-names>Eeva</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Puolakkainen</surname><given-names>Pauli</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pettilä</surname><given-names>Ville</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Repo</surname><given-names>Heikki</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Surgery, Helsinki University Central Hospital, 00029 Helsinki, Finland</aff><aff id="I2"><sup>2</sup>The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, 33521 Tampere, Finland</aff><aff id="I3"><sup>3</sup>Intensive Care Units, Department of Anesthesia and Intensive Care Medicine, Helsinki University Central Hospital, 00029 Helsinki, Finland</aff><aff id="I4"><sup>4</sup>Department of Medicine, University of Helsinki, 00029 Helsinki, Finland</aff><author-notes><corresp id="cor1">*Lea Kyhälä: <email>lea.kyhala@hus.fi</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Derek O'Reilly </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>8</day><month>5</month><year>2012</year></pub-date><volume>2012</volume><elocation-id>712739</elocation-id><history><date date-type="received"><day>24</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Lea Kyhälä et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>The study aimed to determine the effect of the activated protein C on the course of systemic inflammation in the APCAP (activated protein C in acute pancreatitis) trial where we randomized 32 patients with severe acute pancreatitis to receive either recombinant activated protein C (drotrecogin alfa activated) (n = 16) or placebo (n = 16) for 96 hours. </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we present the time course of the patients' plasma or serum levels of soluble markers (IL-8, IL-6, IL-10, IL-1ra, sE-selectin, PCT) and monocyte and neutrophil cell surface (CD11b, CD14, CD62L, HLA-DR) markers of systemic inflammatory response during the first 14 days after the randomization. </plain></SENT>
<SENT sid="4" pm="."><plain>The results of the intervention and placebo groups were comparable showing that recombinant APC treatment did not alter the course of systemic inflammation in severe acute pancreatitis. </plain></SENT>
<SENT sid="5" pm="."><plain>Our finding is in accordance with the clinical findings in the APCAP trial indicating that the intervention did not affect evolution of multiple organ dysfunctions. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="6" pm="."><plain>1. </plain></SENT>
<SENT sid="7" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="8" pm="."><plain>Acute pancreatitis (AP), a common cause of abdominal pain, is usually a mild, self-limited disease. </plain></SENT>
<SENT sid="9" pm="."><plain>However 25% of the patients suffer from severe AP (SAP) [1], and 20% of SAP patients die, [2], mostly due to the development of multiple organ dysfunction [3]. </plain></SENT>
<SENT sid="10" pm="."><plain>Systemic inflammation, typical of AP, is considered to contribute to the development of organ dysfunction. </plain></SENT>
<SENT sid="11" pm="."><plain>It is characterized by (i) an increase in circulating levels of proinflammatory cytokines [4, 5], anti-inflammatory cytokines [6–9], and soluble E-selectin (sE-selectin) [10–12], a marker of activation of the vascular endothelium, (ii) occurrence of activated phagocytes in the circulation [13, 14], and (iii) a decrease in HLA-DR expression on blood monocytes [9, 13, 15, 16], denoting the development of immune suppression. </plain></SENT>
</text></p><p><text><SENT sid="12" pm="."><plain>Activated protein C (APC) is a plasma serine protease with effects on coagulation, apoptosis, and inflammation [17]. </plain></SENT>
<SENT sid="13" pm="."><plain>APC acts as an endogenous anticoagulant that promotes fibrinolysis and inhibits thrombosis. </plain></SENT>
<SENT sid="14" pm="."><plain>Protein C, an inactive precursor, is converted to activate protein C by thrombin-thrombomodulin complex on endothelium [18]. </plain></SENT>
<SENT sid="15" pm="."><plain>This process is accelerated in the presence of endothelial PC receptor (EPCR) [19]. </plain></SENT>
<SENT sid="16" pm="."><plain>APC inactivates the procoagulation factor Va and VIIIa shutting down the coagulation pathway. </plain></SENT>
<SENT sid="17" pm="."><plain>APC also inactivates plasminogen activator inhibitor, which results in increased fibrinolysis [18]. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>APC also has cytoprotective effects such as anti-inflammatory, antiapoptotic, and endothelial barrier protection effects [20]. </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>Proinflammatory cytokines upregulate thrombin formation and downregulate the host's antithrombotic mechanisms, in particular the protein C (PC) pathway reviewed in [21]. </plain></SENT>
<SENT sid="20" pm="."><plain>Deficiency of PC and decreased generation of activated PC (APC), the major endogenous anticoagulant in man, associate with the development of organ dysfunction in AP [22]. </plain></SENT>
<SENT sid="21" pm="."><plain>In patients with sepsis human recombinant APC shortened the duration of respiratory dysfunction and accelerated the reversal of shock [23]. </plain></SENT>
<SENT sid="22" pm="."><plain>We studied in a randomized trial patients with severe AP and found no differences in the evolution of multiorgan dysfunction between APC and placebo groups [24]. </plain></SENT>
<SENT sid="23" pm="."><plain>However, the effects of APC on inflammatory markers in patients with SAP have not been studied in a randomized controlled trial previously. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Accordingly, we aimed to determine the effects of the APC intervention on plasma levels of proinflammatory (IL-8), pro-/anti-inflammatory (IL-6) and anti-inflammatory (IL-10, IL-1ra) [25] cytokines and sE-selectin, on activation markers of blood monocytes (CD14, CD11b, CD62L) and neutrophils (CD11b, CD62L), on levels of monocyte cell-surface expression of HLA-DR, a marker of immune suppression, and on serum levels of procalcitonin (PCT), a marker of systemic inflammation used in clinical decision making. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec2"><title><text><SENT sid="25" pm="."><plain>2. </plain></SENT>
<SENT sid="26" pm="."><plain>Subjects and Methods </plain></SENT>
</text></title><sec sec-type="subsection" id="sec2.1"><title><text><SENT sid="27" pm="."><plain>2.1. </plain></SENT>
<SENT sid="28" pm="."><plain>Patients and Healthy Subjects </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>We previously conducted a randomized study of APC in SAP patients [24]. </plain></SENT>
<SENT sid="30" pm="."><plain>In brief, this prospective randomized double-blind study included analysis of 32 patients with SAP in the tertiary care unit at the Helsinki University Central Hospital between June 2003 and August 2007. </plain></SENT>
<SENT sid="31" pm="."><plain>The inclusion criteria were (1) admitted to hospital &lt;96 h from the onset of pain, (2) a 3-fold increase in serum amylase (IU/L) over normal upper range or/and verification of SAP in computer tomography, (3) at least one organ dysfunction (OD) defined as the Sequential Organ Failure Assessment (SOFA) of at least 3 of 4, and (4) &lt;48 hours from the first OD. </plain></SENT>
<SENT sid="32" pm="."><plain>Patients were randomized to receive either APC (drotrecogin alfa activated) (N = 16) or 0.9% physiologic saline as placebo (N = 16). </plain></SENT>
<SENT sid="33" pm="."><plain>APC was administrated for 96 hours with a dose of 24 μg/kg/hour. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>We obtained reference blood samples for the analyses of cell surface markers by flow cytometry from 65 healthy volunteers (137 samples) from the hospital and laboratory staff without medication and with no signs of infection. </plain></SENT>
<SENT sid="35" pm="."><plain>To monitor the level of fluorescence intensity, a blood sample from a healthy volunteer was studied according to the study protocol once a week. </plain></SENT>
<SENT sid="36" pm="."><plain>There were 58 women and 7 men in the reference group. </plain></SENT>
<SENT sid="37" pm="."><plain>In case of repeated sampling, mean of the data was used. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>The study protocol was approved by the ethics committees of the Helsinki University Central Hospital. </plain></SENT>
<SENT sid="39" pm="."><plain>Informed consent was obtained from all patients or their next of kin. </plain></SENT>
<SENT sid="40" pm="."><plain>The study protocol was registered in <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> (NCT01017107). </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec2.2"><title><text><SENT sid="41" pm="."><plain>2.2. </plain></SENT>
<SENT sid="42" pm="."><plain>Blood Samples </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>When a patient fulfilled the inclusion criteria we collected peripheral blood samples for determination of cell markers of inflammation by venipuncture for the first time. </plain></SENT>
<SENT sid="44" pm="."><plain>Then the patients were randomized. </plain></SENT>
<SENT sid="45" pm="."><plain>After that follow-up samples were collected in the morning of the third, fifth, seventh, and 14th day. </plain></SENT>
<SENT sid="46" pm="."><plain>Blood samples for flow cytometry and for plasma measurements were anticoagulated with pyrogen-free acid-citrate dextrose (ACD). </plain></SENT>
<SENT sid="47" pm="."><plain>Blood samples were immediately cooled in an ice-cold water bath and kept at 0°C until stained for flow cytometry. </plain></SENT>
<SENT sid="48" pm="."><plain>The plasma was separated by centrifugation at +4°C and stored at −70°C until concentrations of cytokines and sE-selectin were determined. </plain></SENT>
<SENT sid="49" pm="."><plain>Blood samples for determination of serum PCT were collected concurrently. </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec2.3"><title><text><SENT sid="50" pm="."><plain>2.3. </plain></SENT>
<SENT sid="51" pm="."><plain>Analysis of Soluble Markers </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>The concentrations of IL-6, IL-8, IL-10, IL-1Ra, and E-selectin in plasma samples were determined by enzyme immunoassay (EIA) by using commercial reagents (IL-6 and IL-10: PeliPair ELISA, Sanquin, Amsterdam, the Netherlands; IL-8: Opt EIA, BD Biosciences, Erembodegem, Belgium; IL-1Ra: Duo Set ELISA, R&amp;D Systems Europe Ltd, Abindgon, UK; E-Selectin: ELISA, HyCult Biotechnology, Uden, The Netherlands). </plain></SENT>
<SENT sid="53" pm="."><plain>The detection limits and intra-assay and interassay coefficients of variation (CV%) were as follows: IL-6: 0.3 pg/mL, 3.6% and 5.4%; IL-8: 1.6 pg/mL, 3.5%, 3.4%; IL-10: 0.3 pg/mL, 3.7%, 5.9%; IL-1Ra: 10 pg/mL, 4.2%, 5.2%; E-selectin 20.5 pg/mL, 3.5%, 6.9%. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>Procalcitonin (PCT) was measured using ADVIA Centaur XP immunoassay system with ADVIA Centaur BRAHMS PCT assay. </plain></SENT>
<SENT sid="55" pm="."><plain>Assay is a sandwich chemiluminescent immunoassay using monoclonal antibody to fluorescein covalently linked to paramagnetic particles and two antibodies to procalcitonin labelled with fluorescein. </plain></SENT>
<SENT sid="56" pm="."><plain>According to the manufacturer, the within-run precision of the method is 4.3%, 1.5%, and 1.5% for PCT at 0.2, 0.97, and 65.9 μg/L, respectively. </plain></SENT>
<SENT sid="57" pm="."><plain>The between-run precision is 8.5%, 2.1%, and 7.2% for the respective concentrations. </plain></SENT>
<SENT sid="58" pm="."><plain>The limit of detection for the assay is 0.04 μg/L and dilution point 75 μg/L. </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec2.4"><title><text><SENT sid="59" pm="."><plain>2.4. </plain></SENT>
<SENT sid="60" pm="."><plain>Analysis of Cell Surface Markers </plain></SENT>
</text></title><p><text><SENT sid="61" pm="."><plain>Monoclonal Antibodies and Flow CytometryMonocyte expression of CD14, CD11b, CD62L and HLA-DR and neutrophil expression of CD62L and CD11b were determined using whole blood flow cytometry, as described previously [9, 13]. </plain></SENT>
<SENT sid="62" pm="."><plain>Monoclonal antibodies (mAbs) were as follows: phycoerythrin (PE) and fluorescein isothiocyanate (FITC) conjugates of anti-CD14 mAb (IgG2b, clone MFP9), PE conjugates of anti-HLA-DR mAb (IgG2a, clone L243), anti CD11b mAb (IgG2a, clone D12) and control mouse IgG2a, mAb, and FITC conjugate of anti-CD62L mAb (IgG2a, clone SK11). </plain></SENT>
<SENT sid="63" pm="."><plain>All reagents were purchased from Becton Dickinson (San Jose, CA, USA). </plain></SENT>
<SENT sid="64" pm="."><plain>Staining of aliquots of the whole blood sample at 0°C for flow cytometry was carried out as described previously [9, 13]. </plain></SENT>
<SENT sid="65" pm="."><plain>Data acquisition and analyses were done by a FACSCalibur flow cytometer and Cell Quest software (BD Sciences, San Jose, CA). </plain></SENT>
<SENT sid="66" pm="."><plain>Neutrophils were identified by the light scattering properties and monocytes by the clonal marker CD14. </plain></SENT>
<SENT sid="67" pm="."><plain>Monocyte HLA-DR expression was determined as the proportion of HLA-DR positive monocytes, as described earlier [13]. </plain></SENT>
<SENT sid="68" pm="."><plain>Fluorescence intensity is presented as relative fluorescence units (RFUs). </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec2.5"><title><text><SENT sid="69" pm="."><plain>2.5. </plain></SENT>
<SENT sid="70" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>The primary end point of the randomized study was the change in SOFA score. </plain></SENT>
<SENT sid="72" pm="."><plain>The sample size for the study was determined according to the primary end point: there would be three-point difference in change of SOFA score between the groups (with P &lt; 0.05 and a power of 80%) [24]. </plain></SENT>
<SENT sid="73" pm="."><plain>Values are given as medians and ranges. </plain></SENT>
<SENT sid="74" pm="."><plain>Comparisons of marker levels between the two groups (the APC group and the placebo group) were performed by the Mann-Whitney U-test. </plain></SENT>
<SENT sid="75" pm="."><plain>In case of repeated sampling from the healthy volunteers mean data was used to get one value for each person and after that median was used. </plain></SENT>
<SENT sid="76" pm="."><plain>The Wilcoxon signed-rank test was used in comparisons of repeated measurements. </plain></SENT>
<SENT sid="77" pm="."><plain>A difference with a P-value of less than 0.05 was considered to be statistically significant. </plain></SENT>
<SENT sid="78" pm="."><plain>Statistical analysis was performed using SPSS19.0 statistical software (Chicago, Illinois). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="sec3"><title><text><SENT sid="79" pm="."><plain>3. </plain></SENT>
<SENT sid="80" pm="."><plain>Results </plain></SENT>
</text></title><sec sec-type="subsection" id="sec3.1"><title><text><SENT sid="81" pm="."><plain>3.1. </plain></SENT>
<SENT sid="82" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>Characteristics of the 32 SAP patients are given in Table 1. </plain></SENT>
<SENT sid="84" pm="."><plain>All except one of the patients were admitted to the ICU. </plain></SENT>
<SENT sid="85" pm="."><plain>The time before patients were admitted to the ICU was 1,0 days (0–3 days) in APC group and 2,0 (1-2 days) in the placebo group (P = 0.642). </plain></SENT>
<SENT sid="86" pm="."><plain>In the APC group there were two nonsurvivors: one after receiving 13 hours of APC infusion and the other one having a laparotomy after 41 hours of APC infusion. </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec3.2"><title><text><SENT sid="87" pm="."><plain>3.2. </plain></SENT>
<SENT sid="88" pm="."><plain>Soluble Markers </plain></SENT>
</text></title><p><text><SENT sid="89" pm="."><plain>Plasma concentrations of proinflammatory cytokine IL-8 of all patients decreased during the first five days after the admission to hospital (day 0: 264 pg/mL versus day 5: 110 pg/mL, P = 0.001). </plain></SENT>
<SENT sid="90" pm="."><plain>The APC treatment had no significant effect on the changes in IL-8 concentrations during the follow-up period (Table 2). </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>Plasma concentrations of pro-/anti-inflammatory cytokine IL-6 (Figure 1), anti-inflammatory cytokines IL-10 and IL-1Ra of all patients decreased during the first five days of the follow-up time (IL-6 day 0: 670 pg/mL versus day 5: 215 pg/mL, P = 0.001; IL-10 day 0: 12.7 pg/mL versus day 5: 11.3 pg/mL, P = 0.001; IL-1Ra day 0: 2890 pg/mL versus day 5: 1250 pg/mL, P = 0.007). </plain></SENT>
<SENT sid="92" pm="."><plain>The APC treatment did not have any significant effect on the changes in IL-6, IL-10, and IL-1Ra concentrations during the first five or 14 days of follow-up time (Table 2). </plain></SENT>
</text></p><p><text><SENT sid="93" pm="."><plain>Plasma concentrations of soluble E-selectin of all patients decreased along the course of the disease (day 0: 45.5 ng/mL versus day 5: 38.2 ng/mL, P = 0.031), but the APC treatment did not have any significant effect on the changes in concentrations of sE-selectin (Table 2). </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>There were no significant changes in serum concentrations of procalcitonin of all patients during the first five days (day 0: 0.97 ng/mL versus day 5: 0.66 ng/mL, P = 0.487), and administration of APC did not alter the changes in PCT concentrations (Table 2). </plain></SENT>
</text></p></sec><sec sec-type="subsection" id="sec3.3"><title><text><SENT sid="95" pm="."><plain>3.3. </plain></SENT>
<SENT sid="96" pm="."><plain>Cell Surface Markers </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>As a marker of immune suppression monocyte HLA-DR expression of all patients was not altered significantly during the first five days of follow-up period (day 0: 54% versus day 5: 58%, P = 0.316). </plain></SENT>
<SENT sid="98" pm="."><plain>Neither had the APC infusion any effect on the HLA-DR expression (Table 3). </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>The cell surface expressions of CD11b, CD14, and CD62L were measured as markers of activation of monocytes. </plain></SENT>
<SENT sid="100" pm="."><plain>The cell surface expression of CD11b, CD14, and CD62L on monocytes of all patients was downregulated during the first five days (MoCD11b day 0: 291 RFU versus day 5: 200 RFU, P = 0.001; MoCD14 day 0: 168 RFU versus day 5: 150 RFU, P = 0.028; MoCD62L day 0: 217 RFU versus day 5: 135 RFU, P = 0.001). </plain></SENT>
<SENT sid="101" pm="."><plain>The expression of CD11b, CD14, and CD62L did not differ significantly between the placebo and the APC-treatment group (Table 3). </plain></SENT>
</text></p><p><text><SENT sid="102" pm="."><plain>The expressions of CD11b and CD62L were measured as markers of neutrophil activation. </plain></SENT>
<SENT sid="103" pm="."><plain>The expressions of CD11b and CD62L (Figure 2) of all patients were both downregulated during the first five days of follow-up period (PMNCD11b day 0: 325 RFU versus day 5: 259 RFU, P = 0.001; neutrCD62L day 0: 146 RFU versus day 5: 81 RFU, P = 0.001). </plain></SENT>
<SENT sid="104" pm="."><plain>The APC treatment did not have any effect on the changes in CD11b or CD62L expression on PMN cells between days 0 and 5 (Table 3). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="sec4"><title><text><SENT sid="105" pm="."><plain>4. </plain></SENT>
<SENT sid="106" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>The results show that recombinant APC (drotrecogin alfa activated) treatment of patients with SAP did not alter the course of systemic inflammation, as determined using soluble and cellular markers of systemic inflammatory response. </plain></SENT>
<SENT sid="108" pm="."><plain>This is in accordance with the clinical findings of these patients, which indicated that SOFA score changes, organ-failure-free days, ICU or hospital stay time, ventilator-free days, renal replacement therapy-free days, vasopressor-free days, or days alive outside hospital (in 60 days) were comparable between APC and placebo groups [24]. </plain></SENT>
<SENT sid="109" pm="."><plain>The overall decreasing tendency of cytokines during the followup resembles earlier results, which show that both pro- and anti-inflammatory bursts are an early phenomenon in severe AP [15]. </plain></SENT>
</text></p><p><text><SENT sid="110" pm="."><plain>Several in vitro and animal studies show that APC has an anti-inflammatory activity. </plain></SENT>
<SENT sid="111" pm="."><plain>Administration of APC has been shown to downregulate the expression of inflammatory cytokines and chemokines. </plain></SENT>
<SENT sid="112" pm="."><plain>APC blocks cytokine production from Th2 lymphocytes [26]. </plain></SENT>
<SENT sid="113" pm="."><plain>APC has been shown to reduce production of endotoxemia-induced proinflammatory cytokines (IL-6, IL-8, IL-1beta, and TNF alfa) [27]. </plain></SENT>
<SENT sid="114" pm="."><plain>In vitro the production of IL-8 from monocytes is inhibited by APC (LPS-stimulated THP-1 cells) [28]. </plain></SENT>
<SENT sid="115" pm="."><plain>In vitro APC has been shown to inhibit chemotaxis and IL-6 release by human neutrophils [29]. </plain></SENT>
<SENT sid="116" pm="."><plain>APC inhibits TNF-alpha production by blocking nuclear factor (NF) kB transcription factor in monocytes [30]. </plain></SENT>
<SENT sid="117" pm="."><plain>APC has been shown to upregulate anti-inflammatory mediators, like IL-10 in blood monocytes in patients with severe sepsis [31]. </plain></SENT>
<SENT sid="118" pm="."><plain>APC can also block leukocyte trafficking by decreasing the expression of adhesion molecules (ICAM-1, E-selectin, and VCAM-1) on the endothelium [32–35]. </plain></SENT>
</text></p><p><text><SENT sid="119" pm="."><plain>Several clinical trials have been established to evaluate the APC treatment in sepsis patients. </plain></SENT>
<SENT sid="120" pm="."><plain>In the PROWESS trial they found that recombinant human activated protein C (drotrecogin alfa) reduced mortality in patients with severe sepsis [36]. </plain></SENT>
<SENT sid="121" pm="."><plain>In this randomized multicentre trial they found decreases in D-dimer levels and IL-6 levels in patients' plasma that has been taken as evidence of anti-inflammatory action of APC [23]. </plain></SENT>
<SENT sid="122" pm="."><plain>HLA-DR expression, as marker of immunosuppression, has been shown to correlate with PC and APC levels in SAP [22]. </plain></SENT>
<SENT sid="123" pm="."><plain>Preliminary, still unpublished results from the PROWESS-SHOCK trial indicated that APC did not have a beneficial effect on 28-day survival in patients with septic shock. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>No previous randomized trial has scrutinized the effect of APC in SAP patients, nor is there such evidence of APC's effect on inflammation in SAP. </plain></SENT>
<SENT sid="125" pm="."><plain>The present study of phlogistic markers supports the view that APC treatment does not affect either the course of systemic inflammation in agreement with no detected effect on organ dysfunction [24]. </plain></SENT>
</text></p><p><text><SENT sid="126" pm="."><plain>Limitations of the study. The sample size for the study (16 + 16) was determined according to the primary end point and not for comparing systemic inflammatory response between the groups. </plain></SENT>
<SENT sid="127" pm="."><plain>In addition the number of follow-up samples/patients was decreased at day five (12 + 14) and at day 14 (11 + 10); therefore it is not possible to exclude a type II error. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="sec5"><title><text><SENT sid="128" pm="."><plain>5. </plain></SENT>
<SENT sid="129" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>The recombinant APC (drotrecogin alfa activated) treatment of patients with SAP did not alter the course of systemic inflammation, as determined using soluble and cellular markers of systemic inflammation. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="131" pm="."><plain>The study was supported by grants from Helsinki University Central Hospital Research funds, Helsinki, Finland and the Competitive Research Funding of Tampere University Hospital, Tampere, Finland. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="ABBR"><glossary><title>Abbreviation</title><def-list><def-item><term>APCAP:</term><def><p>Activated protein C in acute pancreatitis</p></def></def-item><def-item><term>AP:</term><def><p>Acute pancreatitis</p></def></def-item><def-item><term>SAP:</term><def><p>Severe acute pancreatitis</p></def></def-item><def-item><term>PC:</term><def><p>Protein C</p></def></def-item><def-item><term>APC:</term><def><p>Activated protein C</p></def></def-item><def-item><term>PCT:</term><def><p>Procalcitonin</p></def></def-item><def-item><term>OD:</term><def><p>Organ dysfunction</p></def></def-item><def-item><term>SOFA:</term><def><p>Sequential organ failure assessment</p></def></def-item><def-item><term>EIA:</term><def><p>Enzyme immuno assays</p></def></def-item><def-item><term>RFU:</term><def><p>Relative fluorescence units</p></def></def-item><def-item><term>ICU:</term><def><p>Intensive care unit</p></def></def-item><def-item><term>PROWESS:</term><def><p>Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="132" pm="."><plain>1GrönroosJMNylamoEIMortality in acute pancreatitis in Turku University Central Hospital 1971–1995Hepato-Gastroenterology199946282572257410522043 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="133" pm="."><plain>2MofidiRMadhavanKKGardenOJParksRWAn audit of the management of patients with acute pancreatitis against national standards of practiceBritish Journal of Surgery200794784484817330929 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="134" pm="."><plain>3RepineJEScientific perspectives on adult respiratory distress syndromeThe Lancet19923398791466469 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="135" pm="."><plain>4RauBSteinbachGGansaugeFMayerJMGrünertABegerHGThe potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitisGut19974168328409462219 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="136" pm="."><plain>5AounEChenJReighardDGleesonFCWhitcombDCPapachristouGIDiagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysisPancreatology201096777785 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="137" pm="."><plain>6ŠtimacDFišićEMilićSBilić-ZulleLPerićRPrognostic values of IL-6, IL-8, and IL-10 in acute pancreatitisJournal of Clinical Gastroenterology200640320921216633121 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="138" pm="."><plain>7MayerJRauBGansaugeFBegerHGInflammatory mediators in human acute pancreatitis: clinical and pathophysiological implicationsGut200047454655210986216 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="139" pm="."><plain>8HynninenMValtonenMMarkkanenHInterleukin 1 receptor antagonist and E-selectin concentrations: a comparison in patients with severe acute pancreatitis and severe sepsisJournal of Critical Care1999142636810382785 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="140" pm="."><plain>9MentulaPKylänpääM-LKemppainenEPlasma anti-inflammatory cytokines and monocyte human leucocyte antigen-DR expression in patients with acute pancreatitisScandinavian Journal of Gastroenterology200439217818715000282 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="141" pm="."><plain>10Kylänpää-BäckMLTakalaAKemppainenEAProcalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitisCritical Care Medicine2001291636911176162 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="142" pm="."><plain>11PowellJJSiriwardenaAKFearonKCHRossJAEndothelial-derived selectins in the development of organ dysfunction in acute pancreatitisCritical Care Medicine200129356757211373422 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="143" pm="."><plain>12PezzilliRCorsiMMBarassiASerum adhesion molecules in acute pancreatitis: time course and early assessment of disease severityPancreas2008371364118580442 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="144" pm="."><plain>13Kylänpää-BäckM-LTakalaAKemppainenECellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitisScandinavian Journal of Gastroenterology200136101100110711589386 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="145" pm="."><plain>14RahmanSHVerbekeCSGomezDMcMahonMJMenonKVPancreatico-duodenectomy for complicated groove pancreatitisHPB20079322923418333228 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="146" pm="."><plain>15MentulaPKylänpää-BäckMLKemppainenEDecreased HLA (human leucocyte antigen)-DR expression on peripheral blood monocytes predicts the development of organ failure in patients with acute pancreatitisClinical Science2003105440941712780344 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="147" pm="."><plain>16RichterANebeTWendlKHLA-DR expression in acute pancreatitisEuropean Journal of Surgery19991651094795110574102 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="148" pm="."><plain>17ToltlLJAustinRCLiawPCActivated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by reculating endoplasmic reticulum calcium depletion in blood monocytesJournal of Thrombosis and Haemostasis20109582592 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="149" pm="."><plain>18EsmonCTThe protein C anticoagulant pathwayArteriosclerosis and Thrombosis19921221351451311945 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="150" pm="."><plain>19XuJEsmonNLEsmonCTReconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activationThe Journal of Biological Chemistry1999274106704671010037768 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="151" pm="."><plain>20SarangiPPLeeHWKimMActivated protein C action in inflammationBritish Journal of Haematology2010148681783319995397 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="152" pm="."><plain>21LeviMTen CateHDisseminated intravascular coagulationThe New England Journal of Medicine1999341858659210451465 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="153" pm="."><plain>22LindstromOKylanpaaLMentulaPUpregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitisCritical Care2006101, article R16 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="154" pm="."><plain>23BernardGRVincentJ-LLaterreP-FEfficacy and safety of recombinant human activated protein C for severe sepsisThe New England Journal of Medicine20013441069970911236773 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="155" pm="."><plain>24PettilaVKyhalaLKylanpaaMLAPCAP—activated protein C in acute pancreatitis: a double-blind randomized human pilot trialCritical Care2010Article ID R139. </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="156" pm="."><plain>25OpalSMDePaloVAAnti-inflammatory cytokinesChest200011741162117210767254 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="157" pm="."><plain>26YudaHAdachiYTaguchiOActivated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in miceBlood200410362196220414604971 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="158" pm="."><plain>27OkajimaKRegulation of inflammatory responses by natural anticoagulantsImmunological Reviews200118425827411918684 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="159" pm="."><plain>28StephensonDAToltlLJBeaudinSLiawPCModulation of monocyte function by activated protein C, a natural anticoagulantJournal of Immunology2006177421152122 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="160" pm="."><plain>29GalleyHFEl SakkaNEWebsterNRLowesDACuthbertsonBHActivated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functionsBritish Journal of Anaesthesia2008100681581918424805 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="161" pm="."><plain>30YukselMOkajimaKUchibaMHoriuchiSOkabeHActivated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytesThrombosis and Haemostasis200288226727312195699 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="162" pm="."><plain>31ToltlLJBeaudinSLiawPCActivated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytesJournal of Immunology2008181321652173 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="163" pm="."><plain>32GrinnellBWGerlitzBBergDTIdentification of a region in protein C involved in thrombomodulin-stimulated activation by thrombin: potential repulsion at anion-binding site I in thrombinBiochemical Journal1994303, part 39299337980464 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="164" pm="."><plain>33JoyceDEGelbertLCiacciaADeHoffBGrinnellBWGene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosisThe Journal of Biological Chemistry200127614111991120311278252 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="165" pm="."><plain>34NickJAColdrenCDGeraciMWRecombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxisBlood2004104133878388515339848 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="166" pm="."><plain>35SturnDHKaneiderNCFeistritzerCDjananiAFukudomeKWiedermannCJExpression and function of the endothelial protein C receptor in human neutrophilsBlood200310241499150512714492 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="167" pm="."><plain>36BernardGRElyEWWrightTJSafety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsisCritical Care Medicine200129112051205911700394 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="168" pm="."><plain>The changes in concentrations of IL-6 during the follow-up time. </plain></SENT>
<SENT sid="169" pm="."><plain>The APC did not have significant effect on the changes (P = 0.288). </plain></SENT>
<SENT sid="170" pm="."><plain>Box-Whisker plots show median, interquartile range (box) and highest and lowest values. </plain></SENT>
<SENT sid="171" pm="."><plain>Outliers (circles) and extreme values (asterisks) are shown separately. </plain></SENT>
</text></p></caption><graphic xlink:href="IJI2012-712739.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="172" pm="."><plain>The changes in expression of CD62 on neutrophils during the follow-up time. </plain></SENT>
<SENT sid="173" pm="."><plain>The APC did not have significant effect on the changes (P = 0.251). </plain></SENT>
<SENT sid="174" pm="."><plain>Box-Whisker plots show median, interquartile range (box) and highest and lowest values. </plain></SENT>
<SENT sid="175" pm="."><plain>Outliers (circles) are shown separately. </plain></SENT>
</text></p></caption><graphic xlink:href="IJI2012-712739.002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p><text><SENT sid="176" pm="."><plain>Characteristics of patients. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text></text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>Activated protein C </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Placebo </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>No. of patients </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>16 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>16 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Male/female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>16/0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>15/1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>Etiology of SAP -Alcohol/biliary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>16/0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>15/1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>44 (34–36) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>47 (19–59) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>SOFA score on admission </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>8.0 (3–13) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>8.5 (3–15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>ICU stay (days) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>10.0 (2–43) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>11.0 (0–31) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>*Values are median (range).</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p><text><SENT sid="197" pm="."><plain>The changes in concentrations of soluble inflammation markers between days 0–5 and 0–14. </plain></SENT>
<SENT sid="198" pm="."><plain>Median (range). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Marker </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>APC baseline n = 16 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>Placebo baseline n = 16 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>P-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>APC change 0–5 d n = 14 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>Placebo change 0–5 d n = 13 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>P-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>APC change 0–14 d n = 11 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>Placebo change 0–14 d n = 11 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>IL-8, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>286 (56.4–1760) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>245 (41.5–1750) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>0.867 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>−72.3 (−1630–60.8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>−39.5 (−275–470) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>0.159 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>−84.9 (−266–263) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>−132 (−1280–−50.4) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>0.270 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>IL-6, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>798 (93–7190) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>643 (235–41800) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>1.000 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>−377 (−1350–−1090) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>−517 (−41600–−182) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>0.159 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>−724 (−1550–979)5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>−884 (−41700–−388) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>0.288 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>IL-1ra, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>4480 (143–107000) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>2870 (656–12400) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>0.590 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>−2210 (−20500–2160) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>−1480 (−1150–−6380) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>0.627 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>−1500 (−7850–3950) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>−750 (−3890–2240) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>0.243 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>IL-10, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>13.7 (2.78–367) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>10.8 (4.17–145) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>0.724 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>−5.51 (−28.9–6.04) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>−6.72 (−137–28.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>0.438 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>−6.70 (−33.2–72.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>−6.20 (−139–77.0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.898 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>sE-selectin, ng/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>41.4 (25.3–195) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>86.1 (19.0–192) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.445 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.06 (−139–20.0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>−40.5 (−135–16.9) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>0.099 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>0.100 (−143–14.4) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>−45.6 (−144–8.70) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>0.270 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>PCT, ng/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>1.03 (0.12–8.33)1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>0.75 (0.18–3.96)2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>0.880 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>0.18 (−7.53–3.47)3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>−0.21 (−1.91–1.62)4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>0.590 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>0.130 (−4.66–3.96) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>−0.270 (−3.30–2.09)6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0.918 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>1</sup>
<italic>n</italic> = 14, <sup>2</sup>
<italic>n</italic> = 15, <sup>3</sup>
<italic>n</italic> = 11, <sup>4</sup>
<italic>n</italic> = 10, <sup>5</sup>
<italic>n</italic> = 12, <sup>6</sup>
<italic>n</italic> = 10.</p></fn><fn><p>d: day; IL: interleukin; PCT: procalcitonin.</p></fn><fn><p>
<italic>P</italic>-values are calculated for differences between the two groups in changes from baseline.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p><text><SENT sid="269" pm="."><plain>The changes in concentrations of cell markers between days 0–5 and 0–14. </plain></SENT>
<SENT sid="270" pm="."><plain>Median (range). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Marker median, range of healthy reference subjects, n </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>APC baseline   n = 16 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>Placebo baseline n = 15 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>P-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>APC change 0–5 d n = 14 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Placebo change 0–5 d n = 12 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>P-value </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>APC change 0–14 d n = 11 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>Placebo change 0–14 d n = 10 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>MoHLA-DR, % 95.0 (42–99),  n = 64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>54.0 (13–73) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>44.0 (26–75) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.599 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>10.0 (−21–30) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>1.00 (−50–22) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>0.173 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>13.0 (−18–37) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>31.0 (−29–65) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>0.152 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>MoCD11b, RFU 126 (72–297),  n = 63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>284 (118–770) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>337 (136–673) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>0.953 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>−91.5 (−290–123) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>−76.5 (−348–114) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>0.877 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>−35.0 (−301–445) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>−15.0 (−497–150) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>0.349 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>MoCD14, RFU 206 (74–379),  n = 64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>161 (87–306) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>186 (96.0–294) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>0.626 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>−28.5 (−115–68) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>−21.5 (−142–58) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>0.797 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>−5.00 (−75–19) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>−59.5 (−119–60) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>0.173 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>PMNCD11b,  RFU 130 (75–466),  n = 63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>324 (172–791) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>325 (161–519) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>0.861 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>−50.5 (−426–236) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>−66.0 (−219–164) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>0.918 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>−37.0 (−215–242) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>−74.0 (−346–89) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>0.173 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>MoCD62L, RFU 118 (63–279),  n = 64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>217 (133–313) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>216 (87–343) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>0.892 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>−65.5 (−208–15) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>−68.0 (−226–18) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>0.979 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>−95.5 (−212–11) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>−109 (−212–8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>0.481 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>PMNCD62L,  RFU 131 (85–193)  n = 64 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>123 (40–239) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>164  (78–227) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>0.264 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>−46.0 (−212–43) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>−67.5 (−123–25) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>0.898 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>−76.0 (−165–69) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>−80.0 (−165–65) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>0.251 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Mo: monocyte; PMN: neutrophil; RFU: relative fluorescence units.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
